Anti-DFFB Polyclonal Antibody for WB, IHC-P, ELISA - O76075

Core Product Specifications and Parameters

Biological Background: DFFB Function and Localization

• DFFB (DNA fragmentation factor subunit beta), also known as caspase-activated deoxyribonuclease (CAD), CPAN, DFF40, is a key executioner nuclease in apoptosis.
• Encoded by the DFFB gene, it exists as a 39kDa proenzyme that is activated upon caspase-3 cleavage during programmed cell death.
• Its primary function is to induce internucleosomal DNA fragmentation and chromatin condensation, hallmark features of apoptosis.
• DFFB can degrade naked DNA and induce apoptotic nuclear morphology independently of other factors.
• The protein shuttles between the cytoplasm and nucleus; upon activation, it translocates to the nucleus to execute DNA cleavage.
• Alternative splicing generates multiple isoforms, which may have tissue-specific or developmental-specific roles.
• Keywords: Hydrolase, Nuclease, Apoptosis, Cytoplasm, Nucleus, Alternative splicing, 3D-structure.

Experimental Guidance and Technical Tips

• The immunogen (aa 109-338) corresponds to a central domain of DFFB; it may recognize both latent and active forms. Consider validating specificity by comparing treated (apoptotic) vs untreated lysates.
• For WB, a band near 39kDa is expected. Use appropriate positive controls such as apoptotic cell lines (e.g., Jurkat treated with etoposide) and validate in your specific sample system.
• The antibody is compatible with IHC-P and ELISA; optimization of antigen retrieval and blocking conditions may be required for tissue sections.
• Cross-reactivity with mouse DFFB has been validated; for other species, sequence homology should be examined before use.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers and research institutions with a one-stop sourcing platform for IVD raw materials, including validated antibodies like this DFFB polyclonal antibody for apoptosis research. Our supply program covers bulk ancillary reagents, optimized monoclonal/polyclonal pairs, and customized sourcing for rare targets, supporting your projects from concept to clinic.